このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Harpoon Therapeutics 配当金

配当金基準チェック /06

Harpoon Therapeutics配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	2.8%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-US$1.43
3年後の配当利回り予想	0%

最近の配当金アップデート

更新なし

Recent updates

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Jan 30

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Oct 01

Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Aug 14

Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

May 28

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Jul 30

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Jul 07

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Mar 08

We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Nov 30

Harpoon Therapeutics: A First Look

Sep 16

Harpoon shares slide after early-stage prostate cancer study data fails to impress

Jun 04

決済の安定と成長

配当データの取得

安定した配当: HARPの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: HARPの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Harpoon Therapeutics 配当利回り対市場

HARP 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (HARP)	n/a
市場下位25% (US)	1.5%
市場トップ25% (US)	4.7%
業界平均 (Biotechs)	2.8%
3年後のアナリスト予想 (HARP)	0%

注目すべき配当: HARPは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: HARPは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: HARPの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: HARPが配当金を報告していないため、配当金の持続可能性を計算できません。

Harpoon Therapeutics 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

Harpoon Therapeutics Files Form 15

Harpoon Therapeutics, Inc.(NasdaqCM:HARP) dropped from NASDAQ Composite Index

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Consensus estimates of losses per share improve by 16%

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Price target increased by 16% to US$16.33

Harpoon Therapeutics, Inc. Announces Board Changes

Harpoon Therapeutics, Inc. Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Consensus EPS estimates upgraded to US$4.44 loss

Harpoon Therapeutics, Inc. announced that it expects to receive $100.162904 million in funding from a group of investors

New major risk - Share price stability

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Harpoon Therapeutics Receives Non-Compliance Notice from Nasdaq

Harpoon Therapeutics, Inc. Announces Presentation of Interim Data for 2.15 to 12 mg Target Dose Cohorts from its Phase 1 Clinical Trial Evaluating Single-Agent HPN217 in Relapsed/Refractory Multiple Myeloma

Consensus EPS estimates fall by 52%

Price target decreased by 14% to US$45.83

Consensus estimates of losses per share improve by 10%

Forecast to breakeven in 2024

Consensus revenue estimates increase by 57%

Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Price target increased by 11% to US$5.33

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Harpoon Therapeutics, Inc. Appoints Haibo Wang as Senior Vice President of Business Development

Insufficient new directors

Price target decreased by 9.8% to US$4.81

Harpoon Therapeutics, Inc. Announces Completion of Planned Patient Enrollment in Phase 1 Study of Hpn217 in Relapsed/Refractory Multiple Myeloma

Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

Consensus EPS estimates upgraded to US$1.12 loss

Forecast to breakeven in 2024

Consensus EPS estimates fall by 20%, revenue upgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 20% to US$5.43

Consensus revenue estimates fall by 45%

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Harpoon Therapeutics, Inc. Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

Harpoon Therapeutics Receives a Letter from Nasdaq Regarding Minimum Closing Bid Price

Consensus revenue estimates increase by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Harpoon Therapeutics, Inc. Appoints Luke Walker, M.D., as Chief Medical Officer

Harpoon Therapeutics appoints Luke Walker as CMO

Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors

Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player

Price target decreased to US$8.78

Price target decreased to US$10.67

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Harpoon Therapeutics, Inc. Announces Resignation of Georgia L. Erbez as Chief Financial Officer, Effective August 31, 2022

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Harpoon Therapeutics, Inc. Announces Executive Appointments

Harpoon Therapeutics, Inc.(NasdaqGS:HARP) dropped from Russell 2000 Growth Index

Harpoon Therapeutics, Inc. Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Harpoon Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Price target decreased to US$14.50

Harpoon Therapeutics, Inc. Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome

Natalie Sacks to Leave Harpoon Therapeutics, Inc. as Chief Medical Officer, Effective June 1, 2022

Consensus forecasts updated

Price target decreased to US$23.00

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

Harpoon Therapeutics Provides Pipeline Update for TriTAC Clinical Programs and T Cell Engager Platforms

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition

We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.53 loss in 3Q 2020)

Price target decreased to US$26.10

Price target decreased to US$26.70

配当金基準チェック /06